Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a rapid, near-patient testing system for triage and monitoring of disease progression. Its product candidate, an IL-6 Test for sepsis triage, is designed to provide results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and better triage/treatment decisions. The Symphony platform is a combination of its intellectual property (IP) and exclusively licensed and patented IP that consists of a mobile device and single-use test cartridges. The Symphony platform and its initial biomarker test, Symphony IL-6 test, is suited to address a subset of the global in vitro diagnostics devices market, including sepsis, cardio-metabolic diseases, cancer and other diseases that require rapid tests. Symphony targets critical care markets where physicians must quickly determine patient acuity to identify optimal treatment regimens.
BörsenkürzelBJDX
Name des UnternehmensBluejay Diagnostics Inc
IPO-datumNov 10, 2021
CEOMr. Neil (Indranil) Dey
Anzahl der mitarbeiter7
WertpapierartOrdinary Share
GeschäftsjahresendeNov 10
Addresse360 Massachusetts Avenue, Suite 203
StadtACTON
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl01720
Telefon19786310152
Websitehttps://bluejaydx.com/
BörsenkürzelBJDX
IPO-datumNov 10, 2021
CEOMr. Neil (Indranil) Dey
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten